Business Wire

PVH/TOMMY-HILFIGER

13.2.2020 21:59:11 CET | Business Wire | Press release

Share
Tommy Hilfiger Celebrates a More Inclusive Fashion Landscape at Second Edition of Tommy Hilfiger Fashion Frontier Challenge

Tommy Hilfiger, which is owned by PVH Corp. [NYSE: PVH], announces Apon Wellbeing and A Beautiful Mess as winners of the 2019 Tommy Hilfiger Fashion Frontier Challenge . More than 400 applications were received for the second edition of the global program, which aims to support entrepreneurial start-up and scale-up stage businesses developing solutions that promote inclusive and positive change in fashion.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005895/en/

“At Tommy Hilfiger, we’re committed to wasting nothing and welcoming all. From start to finish, I have been inspired by this talented group of social entrepreneurs whose innovations are making the fashion landscape more sustainable and inclusive,” said Tommy Hilfiger. “I am proud to congratulate this year’s winners, Apon Wellbeing and A Beautiful Mess. This is just the beginning for these start-ups and we will continue to mentor and foster these entrepreneurs who are so committed to making a positive impact in our industry.”

“The winners of the second Tommy Hilfiger Fashion Frontier Challenge represent the future of the fashion industry,” said Daniel Grieder, CEO, Tommy Hilfiger Global and PVH Europe. “As our industry continues to rapidly evolve, it is important to collaborate, both within and outside of the fashion landscape, and bring forward innovations that have the ability to transform our businesses for the better. Congratulations to all of the winners and finalists!”

Apon Wellbeing was awarded €75,000. The Bangladesh-based scale-up opens fair-priced shops carrying daily necessities inside factories, with products offered at a 10% discount to external prices and a points scheme that workers collect for free health-insurance and health services.

“When you are upcoming in the fashion value chain, endorsement from a brand like TOMMY HILFIGER immeasurably helps start-ups and scale-ups grow and increase impact,” said Saif Rashid, Apon Wellbeing Founder and Managing Director. “But the most important thing is the strategic support and mentorship the Tommy Hilfiger Fashion Frontier Challenge offers. The support TOMMY HILFIGER has given has already shaped our business model, strategy, communication and how we think about the future.”

Dutch start-up, A Beautiful Mess, was also awarded €75,000. A Beautiful Mess runs a creative space to assist refugees in realizing social and economic independence by creating sustainable apparel products.

“We need big players in the fashion industry to scale-up circular production initiatives, and that’s exactly what the Tommy Hilfiger Fashion Frontier Challenge offers,” said Naz Kawan, A Beautiful Mess Makerspace Director. “A collaborative, integrated approach is necessary if we want to transform the fashion industry’s supply chain. With the support of this global program, we are working towards a more circular, transparent and inclusive fashion landscape.”

The winners also received a year-long mentorship with Tommy Hilfiger’s and INSEAD’s global experts, as well as a place in the INSEAD Social Entrepreneurship Program (ISEP).

A third start-up, Sudara, was selected as the “Audience Favorite Vote” and was awarded €10,000. Based in India and the United States, Sudara is a scale-up pajama and loungewear company that develops professional and sewing skills in women who have escaped from or are at high risk of being sex trafficked.

“The Tommy Hilfiger Fashion Frontier Challenge is all about using fashion as a force for good, which directly speaks to our brand purpose,” said Shannon Keith, Sudara Inc. Founder and Chairwoman. “We’re particularly excited about winning the ‘Audience Favorite Vote,’ because it shows that what we’re doing really resonates with the teams at TOMMY HILFIGER, who are committed to making a difference in the fashion industry.”

Over a multi-step, multi-month process that began in May 2019, over 420 applicants were narrowed down to six finalists who were invited to develop and refine their business plans with the support of a dedicated team of social entrepreneur experts. During the program’s Final Event, which took place at Tommy Hilfiger’s Campus of the Future in Amsterdam, the Netherlands, on February 13, 2020, the six finalists pitched their concepts to a prestigious jury panel, including Mr. Tommy Hilfiger, Daniel Grieder, CEO, Tommy Hilfiger Global and PVH Europe, Noor Tagouri, Journalist, Activist and Speaker, Martijn Hagman, CFO, Tommy Hilfiger Global & COO, Tommy Hilfiger Global and PVH Europe, Willemijn Verloop, Founding Partner, Social Impact Venture, Steven Serneels, CEO and Board Member, EVPA, and Katrin Ley, Managing Director, Fashion for Good.

Tommy Hilfiger’s vision is to create fashion that wastes nothing and welcomes all. Find out more about the brand’s long-term sustainability efforts, particularly in the areas of inclusivity and circularity, at: https://global.tommy.com/en_int/about-us-corporate-sustainability .

Friends and followers of the brand are invited to join the conversation on social media using #TommyHilfiger and @TommyHilfiger.

About Tommy Hilfiger

With a brand portfolio that includes TOMMY HILFIGER and TOMMY JEANS , Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER and TOMMY JEANS brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER and TOMMY JEANS retail stores, leading specialty and department stores, select online retailers, and at tommy .com.

About PVH Corp.

PVH sets the standard of style as one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our iconic portfolio includes TOMMY HILFIGER , CALVIN KLEIN , Van Heusen , IZOD , ARROW , Speedo *, Warners , Olga and Geoffrey Beene brands, as well as the digital-centric True & Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 38,000 associates operating in over 40 countries and nearly $9.7 billion in annual revenues. That’s the power of PVH.

*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International Limited.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye